Compile Data Set for Download or QSAR
Report error Found 9 Enz. Inhib. hit(s) with all data for entry = 2013
TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350693(US9795602, Compound 29)
Affinity DataIC50: 216nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350694(US9795602, Compound 58)
Affinity DataIC50: 2.49E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350830(US9795602, Compound 59)
Affinity DataIC50: 2.51E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350834(US9795602, Compound 12)
Affinity DataIC50: 6.40E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350835(US9795602, Compound 25b)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350836(US9795602, Compound 28)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350833(US9795602, Compound 39)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350831(US9795602, Compound 31)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
US Patent

TargetPOU domain, class 2, transcription factor 2(Human)
Gilead Sciences

US Patent
LigandPNGBDBM350832(US9795602, Compound 32)
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/23/2019
Entry Details
US Patent